Read more about us
Sprint Bioscience is a pharmaceutical company with a focus on developing drugs for cancer
The company was founded in 2009 by an entrepreneurial team of five people, four from the Swedish pharmaceutical industry, with the aim of building a pharmaceutical company with cutting-edge expertise in preclinical drug development. The common driving force for everyone in the company is the opportunity to make a difference and to develop drugs that reach the market, something that characterizes all activities.
At Sprint Bioscience, we believe that the key to effectively running projects is close collaboration and interaction between the different scientific disciplines involved in the work. To enable this, we have chosen to invest in internal expertise. We have recruited the best in their fields and built up the key competencies needed for preclinical drug development.
Sprint Bioscience currently has about 35 employees, the majority of whom work in the laboratory within the company's drug development projects.
Meet the management behind our research
Johan Emilsson
Martin Andersson
Anne-Marie Wenthzel
Niklas Axelsson
Meet the Board of Directors behind the company
Björn Sjöstrand
Svein Mathisen
Rune Nordlander
Fredrik Lehmann
Karen From
Read more about the members of Council
Gunilla Enblad
Read more about GunillaGunilla is Professor of Oncology at Uppsala University since 2013 and Senior Consultant at Uppsala University Hospital. Her research areas include clinical and tumor biology studies of malignant lymphomas, as well as immunotherapy including clinical studies of CAR T cells.
Since 2019, she is the chair of the Swedish CAR T-cell group and is also a scientific advisor to XNK-therapeutics and Elicera Therapeutics.
She is a board member of the Swedish Cancer Society and the Department of Immunology, Genetics and Pathology at Uppsala University. Since 2017, she is also a member of the Royal Society of Science in Uppsala.
Robert J Devita
Read more about Robert J DevitaRobert has been a principal consultant for RJD Med Chem and Drug Discovery Consulting LLC since 2013. He has over 30 years of experience in early stage research and drug development working in biotech, pharmaceutical industry and academia. At Merck Research Laboratories, he was Director of Medicinal Chemistry and was responsible for six different programs that advanced drug candidates into clinical development, including several that reached human clinical trials. He has also been Vice President, Chemistry at Agios, a company focused on early drug development in oncology.
For the past 10 years, he has run a medicinal chemistry consulting company and supported other companies in all phases of drug development, including the development of IP strategies and due diligence activities related to licensing deals.
He is also a member of the Medicinal Chemistry Division of the American Chemical Society, and holds several leadership positions.
Lewis C. Cantley
Read more about Lewis C. CantleyLewis C. Cantley is a professor at the Dana Farber Cancer Institute. He is a cell biologist and biochemist who has made groundbreaking discoveries in the field of cancer metabolism. Among his most notable contributions is the discovery and study of the enzyme PI-3 kinase, an enzyme of great importance in diseases such as cancer and diabetes. He was previously Meyer Director and Professor of Cancer Biology at the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine in New York City.
He has also held positions as Professor in the Departments of Systems Biology and Medicine at Harvard Medical School and Director of Cancer Research at Beth Israel Deaconess Medical Center in Boston.
Professor Cantley is also a co-founder of several biotech companies focused on oncology, including Agios Pharmaceuticals, Petra Pharma and Volastra Therapeutics.
In 2016, he was elected Chairman of the Board of The Hope Funds for Cancer Research. Over the years, the funds have received several scientific awards for their research.